Psychiatr. praxi 2018; 19(2): 76-79 | DOI: 10.36290/psy.2018.016

Older patient treated with pregabalin for generalized anxiety disorder: a case study

doc. MUDr. Bc. Libor Ustohal, Ph.D.1,2
1 Psychiatrická klinika LF MU a FN Brno
2 Středoevropský technologický institut Masarykovy univerzity (CEITEC MU), Brno

Pregabalin is used with an increasing frequency for the treatment of generalized anxiety disorder. It is supposed to decreaseexcitatory neurotransmission by binding to the α2δ subunit of the P/Q-type of voltage-gated calcium channel. This case studypresents its efficacy and safety even in elderly. Moreover, pregabalin reduced the use of benzodiazepines as well as it influencedpain syndrome in our patient.

Keywords: generalized anxiety disorder, GAD, pregabalin, elderly, benzodiazepines, pain syndrome

Published: June 26, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ustohal L. Older patient treated with pregabalin for generalized anxiety disorder: a case study. Psychiatr. praxi. 2018;19(2):76-79. doi: 10.36290/psy.2018.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Frampton JE. Pregabalin: A review of its use in adults with generalized anxiety disorder. CNS Drugs 2014; 28: 835-854. Go to original source... Go to PubMed...
    2. Hýža M. Pregabalin v léčbě generalizované úzkostné poruchy. Psychiatr praxi 2017; 18(2): 78-80. Go to original source...
    3. Kessler RC, Wang PS. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 2008; 29: 115-129. Go to original source... Go to PubMed...
    4. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 357-376. Go to original source... Go to PubMed...
    5. Baldwin DS, den Boer JA, Lyndon G, Emir B, Schweizer E, Haswell H. Efficacy and safety of pregabalin in generalized anxiety disorder: A critical review of the literature. J Psychopharmacol 2015; 29(10): 1047-1060. Go to original source... Go to PubMed...
    6. Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry 2001; 62(suppl. 11): 15-19.
    7. Hajda M, Kamarádová D, Praško Pavlov J. Léčba generalizované úzkostné poruchy pomocí pregabalinu. Psychiatr praxi 2015; 16(3): 101-104.
    8. Mackintosh MA, Gatz M, Wetherell JL, Pedersen NL. A twin study of lifetime generalized anxiety disorder (GAD) in older adults: genetic and environmental influences shared by neuroticism and GAD. Twin Res Hum Genet 2006; 9: 30-37. Go to original source...
    9. Švestka J, Doležal T. Pregabalin - nové nebenzodiazepinové anxiolytikum. Psychiatrie 2007; 11(1): 24-30.
    10. Ehler E. Farmakologický profil pregabalinu (Lyrica). Neurol praxi 2014; 15(6): 350-354.
    11. Ambler Z. Pregabalin v léčbě neuropatické bolesti. Farmakoterapie 2011; 7(suppl. 1): 49-52.
    12. Sekot M. Může být pregabalin efektivní u léčby deprese? Klin Farmakol Farm 2017; 31(3): 7-8. Go to original source...
    13. Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol 2017; 32(1): 49-55. Go to original source... Go to PubMed...
    14. Bednařík J. Farmakoterapie neuropatické bolesti ve světle medicíny založené na důkazech. Bolest 2014; 17(2): 41-46.
    15. Tkáč J. Pregabalin v léčbě generalizované úzkosti a lékové závislosti na alprazolamu. Psychiatr praxi 2015; 16(1): 24-26.
    16. Kmoch V. Pacient s generalizovanou úzkostí a jeho závislost na zolpidemu - léčba pregabalinem a motivační rozhovory. Psychiatr praxi 2015; 16(2): 60-63.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.